Status:
COMPLETED
An Observational Study of Herceptin SC Safety in Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous admi...
Eligibility Criteria
Inclusion
- \- All patients administered Herceptin SC for the locally approved indications
Exclusion
- N/A
Key Trial Info
Start Date :
June 26 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2020
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT02305628
Start Date
June 26 2015
End Date
January 31 2020
Last Update
November 16 2020
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Hospital
Busan, South Korea, 49241
2
Kosin University Gospel Hospital
Busan, South Korea, 49267
3
Keimyung University Dongsan Medical Center
Daegu, South Korea, 41931
4
Myongji Hospital
Gyeonggi-do, South Korea, 10475